This is a Phase IV, single site, randomized, double masked, parallel control clinical trial
of 60 subjects to investigate the variance of efficacy between Lotemax® and Zylet® for
treatment of ocular surface inflammation due to meibomian gland dysfunction (MGD). Efficacy
will be measured by in-vivo confocal microscopy, corneal fluorescein staining, grading of
meibomian gland dysfunction and validated ocular symptom assessment questionnaire.